At Fungi Therapy Hub, scientific accuracy, chemical precision, and editorial independence form the bedrock of our journalism. This document outlines the standards and methodologies governing our research and publication processes.
1. Peer-Reviewed Academic Evidence
Every scientific claim, pharmacological evaluation, and receptor affinity metric published on Fungi Therapy Hub must be substantiated by primary literature. Our primary sources include:
- Peer-reviewed journals indexed in PubMed, MEDLINE, and Web of Science (e.g., ACS Chemical Neuroscience, Nature Neuropsychopharmacology, The Lancet Psychiatry, Frontiers in Pharmacology).
- Clinical trial data registered with official registries (such as ClinicalTrials.gov and the EU Clinical Trials Register).
- Analytical chemical monographs and reference libraries from certified institutions (e.g., Cayman Chemical, SWGDRUG, Alexander Shulgin Research Institute).
2. Chemical and Pharmacological Precision
In an ecosystem frequently compromised by slang, marketing obfuscation, and gray-market mislabeling, we maintain strict chemical taxonomy:
- Substances are identified by standard IUPAC nomenclature, common chemical aliases, and CAS registry numbers where applicable.
- Receptor binding values (Ki, EC50, Emax) are contextualized alongside experimental assay methodologies to prevent misleading cross-study comparisons.
- Prodrug metabolic pathways (e.g., dephosphorylation of psilocybin, ester hydrolysis of 4-AcO-DMT and 4-PrO-DMT) are differentiated from parent molecular dynamics based on validated pharmacokinetic research.
3. Editorial Independence & Conflict of Interest Policy
Fungi Therapy Hub maintains strict firewalls between editorial reporting and commercial monetization:
- Zero Commercial Control: Advertisers, sponsors, and affiliate partners have no preview privileges, editorial oversight, or veto authority over our investigative reporting or scientific conclusions.
- Uncompromising Harm Warnings: We will never omit, soften, or delay publishing safety alerts, adulterant findings, or cardiovascular risk warnings (e.g., 5-HT2B valvulopathy risks) to satisfy any commercial partner.
4. Fact-Checking, Corrections & Transparency
Scientific consensus evolves. When new empirical data refutes, qualifies, or expands upon previous analyses, we promptly update our published guides with clear revision notes.
If you identify a factual error, ambiguous pharmacological metric, or outdated citation, please notify our editorial desk at [email protected] with the article URL and supporting academic references.